In September of 2004, Genteric Inc was dissolved by the US Bankrupcy court of Northern California. Genteric, Inc. is a biotech company commercializing gene delivery platforms and creating new and improved protein drug therapies. Genteric is focused on the development of several proprietary technology platforms that harness the body's own protein production and distribution system. Using improved, non-viral and viral gene delivery techniques, Genteric's unique approach converts genes to therapeutic proteins within the patient's salivary glands and other gastrointestinal organs. Genteric is pioneering an innovative therapeutic approach called The Genteric Method â a gene delivery system that utilizes the body's digestive organs to produce protein biopharmaceuticals. The Gene Pill⢠focuses on orally available, non-viral gene therapies by absorption of genes in the intestines. The Retroductal Delivery Program focuses on both viral and non-viral gene delivery to the salivary glands and the liver, both through simple non-surgical procedur
